News|Articles|May 26, 2026

Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion

Listen

0:00 / 0:00

Key Takeaways

Positioning shifts from treatment to prophylaxis, using vaccines to blunt antimicrobial resistance-driven unmet need and mitigate infection-associated long-term morbidity, including neurological disease, malignancy, and infertility.
Curevo’s amezosvatein delivered Phase II noninferior immune responses versus the shingles standard while cutting activity-limiting systemic and injection-site reactogenicity by more than 50%.
LimmaTech expands bacterial coverage against S. aureus, N. gonorrhoeae, and C. trachomatis, leveraging immune targeting of toxins/superantigens to potentially improve breadth and durability beyond surface-antigen approaches.
The Vaccine Company’s in vivo nanoparticle platform aims to simplify VLP-like vaccine manufacturing and advances a Phase I-ready, five-antigen EBV candidate with implications for MS and EBV-associated cancers.

Eli Lilly enters three separate acquisitions totaling $3.83 billion in a push into vaccines and infectious diseases, signaling a strategic expansion into prevention-focused medicines.

Eli Lilly announced agreements to acquire three vaccine and infectious disease companies.

The push will deploy upwards of $3.83 billion to build out a prevention-focused infectious disease platform and marking a significant strategic expansion beyond the company's established cardiometabolic and oncology franchises.

What is the strategic rationale?

Lilly framed its three acquisitions around the idea that preventing infections at their source is increasingly preferable to treating their consequences, particularly as antimicrobial resistance erodes the effectiveness of existing antibiotics, and as mounting evidence links common infections to serious downstream diseases including neurological conditions, cancer, and infertility.¹

"These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," said Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer and president of Lilly Research Laboratories. "As antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory."

Curevo, up to $1.5 billion for a better-tolerated shingles vaccine

The first of Lilly’s three acquisitions, is Curevo. The focus of the acquisition is the company’s lead asset, amezosvatein, an adjuvanted subunit vaccine for shingles prevention engineered with a next-generation synthetic adjuvant designed to improve tolerability over the current standard of care.¹

In a Phase II head-to-head trial, amezosvatein matched immune response across all primary endpoints while reducing activity-limiting fatigue, chills, and injection-site pain by more than half compared to the existing vaccine.¹

Per the terms of the acquisition agreement, Curevo shareholders are set to receive upwards of $1.5 billion in cash, inclusive of an upfront payment and subsequent payment upon achievement of a specified milestone.²

The strategic case goes beyond tolerability as growing evidence links shingles to elevated stroke risk. Shingles vaccination has been associated with reduced dementia risk, meaning a more widely adopted vaccine could have population-level neurological benefits.

LimmaTech Biologics, up to $780 million for bacterial vaccines

The second acquisition from Elil Lilly is LimmaTech. The company is currently developing vaccines against bacterial pathogens including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis, all targets where rising antimicrobial resistance is progressively limiting treatment options.²

LimmaTech’s platform is designed to generate broad, durable immune responses by targeting toxins and superantigens that drive disease rather than surface antigens alone. Its lead program, LTB-SA7, is in Phase I development as a vaccine against S. aureus, the leading cause of surgical-site infection.¹The preclinical pipeline also targets pathogens responsible for infertility and other long-term consequences that fall disproportionately on women.

In total, Lilly will acquire LimmaTech for nearly $780 million in cash, inclusive of an upfront payment, along with additional potential payments based upon the achievement of certain clinical and regulatory milestones.¹

Vaccine Company, $1.55 billion for EBV vaccine platform

The last of Lilly’s three new acquisitions is the Vaccine Company. The company is developing In Vivo Nanoparticle technologies that enable antigen display associated with durable immune responses from virus-like particle vaccines, while eliminating the manufacturing complexity of traditional VLP production.¹

Its lead program applies the In Vivo Nanoparticle technology to Epstein-Barr Virus, with a five-antigen Phase I-ready candidate.¹ The scientific rationale is compelling as EBV has been linked to multiple sclerosis and several malignancies, meaning a prophylactic vaccine could prevent not only acute mononucleosis but also the long-term neurological and oncological consequences that may follow primary infection.¹

Together, the three acquisitions position Lilly as a serious player in vaccine-led infectious disease prevention across viral, bacterial, and AMR-related threats.

Sources

Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly and Company May 26, 2026 https://www.prnewswire.com/news-releases/lilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-302781404.html
Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push Reuters May 26, 2026 https://www.reuters.com/legal/transactional/lilly-acquire-three-vaccine-developers-4-billion-2026-05-26/

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.